Author

C. Atyeo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 7

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Research Focus:host-pathogen & immune response· 7 Research Focus:drug response / drug discovery· 3 Organism:non-human primate· 3 Assay:proteomics· 3 Research Focus:cell type annotation· 2 Research Focus:cell-cell communication· 2 Organism:human· 2

Frequent Co-Authors

G. Alter· 4 shared S. Fischinger· 4 shared M. J. Gorman· 3 shared A. Fasano· 2 shared A. G. Edlow· 2 shared A. Zhu· 2 shared D. A. Lauffenburger· 2 shared E. A. Bordt· 2 shared

Activity by Year

2020-2022 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

G. Alter

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

A monkeypox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives protection against lethal orthopoxviral challenge

A. W. Freyn, C. Atyeo, P. L. Earl, J. L. Americo, G.-Y. Chuang, H. Natarajan, T. R. Frey, J. Gall, J. I. Moliva, R. Hunegnaw, G. Asthagiri Arunkumar, C. Ogega, A. Nasir, H. Bennett, J. Johnson, , B. Moss

This paper develops an mRNA-lipid nanoparticle vaccine targeting four conserved MPXV surface proteins, showing superior protection against VACV compared to MVA.

bioRxiv · Dec 17, 2022 · PreprintImmunology

COVID-19 mRNA vaccines drive differential Fc-functional profiles in pregnant, lactating, and non-pregnant women

C. Atyeo, E. A. Deriso, C. Davis, E. A. Bordt, R. M. De Guzman, L. L. Shook, L. M. Yonker, A. Fasano, B. Akinwunmi, D. A. Lauffenburger, M. A. Elovitz, K. J. Gray, A. G. Edlow, G. J. Alter

This study examines how mRNA vaccines affect Fc-functional antibody profiles in pregnant, lactating, and non-pregnant women, finding delayed kinetics and altered immune responses in pregnant and lactating individuals.

bioRxiv · Apr 4, 2021Immunology

Sexually dimorphic placental responses to maternal SARS-CoV-2 infection

E. A. Bordt, L. L. Shook, C. Atyeo, K. M. Pullen, R. M. De Guzman, M.-C. Meinsohn, M. Chauvin, S. Fischinger, L. J. Yockey, K. James, R. Lima, L. M. Yonker, A. Fasano, S. Brigida, L. M. Bebell, , A. G. Edlow

The paper investigates sex differences in placental responses to maternal SARS-CoV-2 infection, finding sex-specific changes in interferon genes, Fc-receptor expression, and antibody transfer.

bioRxiv · Mar 29, 2021 · PreprintImmunology

Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates

J. R. Francica, B. J. Flynn, K. E. Foulds, A. T. Noe, A. P. Werner, I. N. Morre, M. Gagne, T. S. Johnston, C. Tucker, R. L. Davis, B. Flach, S. O'Connell, S. F. Andrew, E. Lamb, D. R. Flebbe, , McDermott

This study shows that an AS03-adjuvanted SARS-CoV-2 spike protein vaccine induces strong antibody responses and protects nonhuman primates from viral challenge.

bioRxiv · Mar 2, 2021 · PreprintImmunology

Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates

P. S Arunachalam, A. C. Walls, N. Golden, C. Atyeo, S. Fischinger, C. Li, P. Aye, M. J. Navarro, L. Lai, V. V. Edara, K. Roltgen, K. Rogers, L. Shirreff, D. E. Ferrell, S. Wrenn, , Coffma

This study evaluates adjuvants for a subunit SARS-CoV-2 nanoparticle vaccine in non-human primates, showing durable neutralizing antibody responses and protection against infection.

bioRxiv · Feb 10, 2021 · PreprintImmunology

Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination

M. J. Gorman, N. Patel, M. Guebre-Xabier, A. Zhu, C. Atyeo, K. Pullen, C. Loos, Y. Goez-Gazi, R. Carrion, J.-H. Tian, D. Yuan, K. Bowman, B. Zhou, S. Maciejewski, M. McGrath, , G. Alter

This study shows that NVX-CoV2373 vaccine induces antibodies with both neutralizing and Fc-effector functions, which together provide maximal protection against SARS-CoV-2 in non-human primates.

bioRxiv · Feb 5, 2021 · PreprintImmunology

Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response

N. K. Routhu, S. Gangadhara, N. Cheedarla, A. Shiferaw, S. A. Rahman, A. Sahoo, P.-Y. Shi, V. D. Menachery, K. Floyd, S. Fischinger, C. Atyeo, G. Alter, M. S. Suthar, R. R. Amara

This study develops two MVA-based SARS-CoV-2 vaccines, MVA/S and MVA/S1, and finds that MVA/S induces stronger neutralizing antibodies against SARS-CoV-2 compared to MVA/S1.

bioRxiv · Jun 27, 2020 · PreprintImmunology